SGLT inhibitors and euglycaemic diabetic ketoacidosis: earlier observations rediscovered

Salem A Beshyah, Brian M Frier

Abstract


Diabetic ketoacidosis (DKA) is a life-threatening metabolic derangement, defined by the presence of severe hyperglycaemia, ketosis and metabolic acidosis. Recently, DKA was redefined to be present when the latter two abnormalities occur without severe hyperglycaemia. Munro and colleagues in Edinburgh described ‘euglycaemic diabetic ketoacidosis’ in 1973 and suggested this new terminology. The same year the critical feature of this subclass of DKA – that is, an increased urinary loss of glucose – was identified by Ireland and Thomson in Glasgow. In the subsequent 40 years (from 1974 to 2014), clinical interest in this condition was limited to a few case reports. The emergence of a new class of antidiabetes medications, the sodium-glucose cotransporter (SGLT) inhibitors, which promote profuse glycosuria, has reawakened interest in euglycaemic DKA, as this is a side effect of these drugs. The earlier perceptive observations of these physicians in Scotland deserve to be recognised for their contribution in identifying and describing euglycaemic DKA and correctly identifying its underlying pathogenesis. Recent international consensus has provided guidance to physicians to aid timely recognition of the condition by testing for ketosis in the appropriate clinical context and to manage it effectively by discontinuing the SGLT inhibitor and provision of insulin, carbohydrate and hydration (the STICH protocol). This may be particularly relevant in view of the recent licensing developments for use of certain members of the SGLT inhibitors in type 1 diabetes.


Keywords


DKA, euglycaemic diabetic ketoacidosis, SGLT inhibitor, type 1 diabetes, urinary glucose

Full Text:

PDF HTML

References


Savage MW, Dhatariya KK, Kilvert A, et al for the Joint British Diabetes Societies. Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis. Diabet Med 2011;28(5):508–15. https://doi.org/10.1111/j.1464-5491.2011.03246.x

Munro JF, Campbell IW, MacCuish AC, et al. Euglycaemic diabetic ketoacidosis. Br Med J 1973;2(5866):578–80.

Ireland JT, Thomson WST. Euglycaemic diabetic ketoacidosis. Br Med J 1973;3(5871):107 (letter).

Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018;61(12):2461–98. https://doi.org/10.1007/s00125-018-4729-5

Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019;393(10166):31–9. https://doi.org/10.1016/S0140-6736(18)32590-X

Ueda P, Svanström H, Melbye, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 2018;363:k4365. https://doi.org/10.1136/bmj.k4365

Modi A, Agrawal A, Morgan F. Euglycemic diabetic ketoacidosis: a review. Curr Diabetes Rev 2017;13(3):315–21. https://doi.org/10.2174/1573399812666160421121307

Rawla P, Vellipuram AR, Bandaru SS, et al. Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma. Endocrinol Diabetes Metab Case Rep 2017;2017. pii: 17-0081. https://doi.org/10.1530/EDM-17-0081

Perry RJ, Rabin-Court A, Song JD, et al. Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats. Nat Commun 2019;10(1):548. https://doi.org/10.1038/s41467-019-08466-w

Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015;38(9):1687–93. https://doi.org/10.2337/dc15-0843

Garg SK, Peters AL, Buse JB, Danne T. Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: a STICH protocol. Diabetes Technol Ther 2018;20(9):571–5. https://doi.org/10.1089/dia.2018.0246

Danne T, Garg S, Peters AL, Buse JB, et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care 2019 Feb 6. pii: dc182316. https://doi.org/10.2337/dc18-2316

European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Summary of opinion (initial authorisation): Zynquista (sotagliflozin). Available at: https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zynquista_en.pdf (last accessed 1 May 2019).

Dandona P, Mathieu C, Phillip M, et al; DEPICT-1 Investigators. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study. Diabetes Care 2018; 41(12):2552–9. https://doi.org/10.2337/dc18-1087




DOI: https://doi.org/10.15277/bjd.2019.214

Refbacks

  • There are currently no refbacks.


The Journal of the Association of British Clinical Diabetologists